Generate Biomedicines, Inc. Common Stock (GENB) is a publicly traded the market company. As of August 21, 2026, GENB trades at $16.18 with a market cap of $2.18B and a P/E ratio of -30.73. GENB moved +1.47% today. Year to date, GENB is +0.00%; over the trailing twelve months it is flat. Its 52-week range spans $11.00 to $18.18. Analyst consensus is strong buy with an average price target of $26.33. Rallies surfaces GENB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
3 analysts cover GENB: 0 strong buy, 3 buy, 0 hold, 0 sell, and 0 strong sell. The consensus rating is strong buy. The average price target is $26.33.
| Metric | Value |
|---|---|
| Price | $16.18 |
| Market Cap | $2.18B |
| P/E Ratio | -30.73 |
| EPS | $-0.52 |
| Dividend Yield | 0.00% |
| 52-Week High | $18.18 |
| 52-Week Low | $11.00 |
| Volume | 358.01K |
| Avg Volume | 0 |
| Revenue (TTM) | $6.31M |
| Net Income | $-67.25M |
| Gross Margin | 0.00% |
3 analysts cover GENB: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $26.33.